Journal
BMC CANCER
Volume 18, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12885-018-4146-7
Keywords
Combined hepatocellular cholangiocarcinoma (CHCC-CC); Midkine (MK); Early recurrence; Prognosis
Categories
Funding
- Kaohsiung Chang Gung Memorial Hospital Taiwan [CMRPG8E0881, CMRPG8C0531, CMRPG8D0801]
Ask authors/readers for more resources
Background: Post-surgical prognosis is usually poor for combined hepatocellular cholangiocarcinoma (CHCC-CC), a rare primary liver cancer. Although midkine (MK) is a prognostic biomarker for several known cancers, it is not known whether it can be used as such in resectable CHCC-CC. This study examined whether MK expression can predict recurrence and survival in patients with resectable CHCC-CC. Methods: We retrospectively enrolled 52 patients with resectable CHCC-CC who had received curative hepatic resections. MK expression was assessed in post-surgical immunohistochemical studies of specimens in paraffin blocks. Clinical outcomes were analyzed from medical records. Results: Two-year disease-free and three-year overall survival rates were 42.1% and 44.6%. MK was expressed in 30 patients. Univariate analysis showed patients positively expressing MK had a significantly poorer 2-year disease free and three-year overall survival. Multivariate analysis found positive MK expression independently predicted recurrence. Conclusions: Positive expression of MK predicts poor prognosis in patients with resectable CHCC-CC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available